Low dose evaluation of the antiandrogen flutamide following a Mode of Action approach
The dose–response characterization of endocrine mediated toxicity is an on-going debate which is controversial when exploring the nature of the dose–response curve and the effect at the low-end of the curve. To contribute to this debate we have assessed the effects of a wide range of dose levels of...
Saved in:
Published in | Toxicology and applied pharmacology Vol. 289; no. 3; pp. 515 - 524 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
15.12.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The dose–response characterization of endocrine mediated toxicity is an on-going debate which is controversial when exploring the nature of the dose–response curve and the effect at the low-end of the curve. To contribute to this debate we have assessed the effects of a wide range of dose levels of the antiandrogen flutamide (FLU) on 7-week male Wistar rats. FLU was administered by oral gavage at doses of 0, 0.001, 0.01, 0.1, 1 and 10mg/kg/day for 28days. To evaluate the reproducibility, the study was performed 3 times. The molecular initiating event (MIE; AR antagonism), the key events (LH increase, Leydig cell proliferation and hyperplasia increases) and associated events involved in the mode of action (MOA) of FLU induced testicular toxicity were characterized to address the dose response concordance. Results showed no effects at low doses (<0.1mg/kg/day) for the different key events studied. The histopathological changes (Leydig cell hyperplasia) observed at 1 and 10mg/kg/day were associated with an increase in steroidogenesis gene expression in the testis from 1mg/kg/day, as well as an increase in testosterone blood level at 10mg/kg/day. Each key event dose–response was in good concordance with the MOA of FLU on the testis. From the available results, only monotonic dose–response curves were observed for the MIE, the key events, associated events and in effects observed in other sex related tissues. All the results, so far, show that the reference endocrine disruptor FLU induces threshold effects in a standard 28-day toxicity study on adult male rats.
•Dose–response characterization of endocrine mediated toxicity is an on-going debate.•A wide range of dose levels of flutamide was evaluated on young adult male rats.•Flutamide induces threshold effects using on standard and molecular tools. |
---|---|
AbstractList | The dose-response characterization of endocrine mediated toxicity is an on-going debate which is controversial when exploring the nature of the dose-response curve and the effect at the low-end of the curve. To contribute to this debate we have assessed the effects of a wide range of dose levels of the antiandrogen flutamide (FLU) on 7-week male Wistar rats. FLU was administered by oral gavage at doses of 0, 0.001, 0.01, 0.1, 1 and 10mg/kg/day for 28days. To evaluate the reproducibility, the study was performed 3 times. The molecular initiating event (MIE; AR antagonism), the key events (LH increase, Leydig cell proliferation and hyperplasia increases) and associated events involved in the mode of action (MOA) of FLU induced testicular toxicity were characterized to address the dose response concordance. Results showed no effects at low doses (<0.1mg/kg/day) for the different key events studied. The histopathological changes (Leydig cell hyperplasia) observed at 1 and 10mg/kg/day were associated with an increase in steroidogenesis gene expression in the testis from 1mg/kg/day, as well as an increase in testosterone blood level at 10mg/kg/day. Each key event dose-response was in good concordance with the MOA of FLU on the testis. From the available results, only monotonic dose-response curves were observed for the MIE, the key events, associated events and in effects observed in other sex related tissues. All the results, so far, show that the reference endocrine disruptor FLU induces threshold effects in a standard 28-day toxicity study on adult male rats. The dose–response characterization of endocrine mediated toxicity is an on-going debate which is controversial when exploring the nature of the dose–response curve and the effect at the low-end of the curve. To contribute to this debate we have assessed the effects of a wide range of dose levels of the antiandrogen flutamide (FLU) on 7-week male Wistar rats. FLU was administered by oral gavage at doses of 0, 0.001, 0.01, 0.1, 1 and 10 mg/kg/day for 28 days. To evaluate the reproducibility, the study was performed 3 times. The molecular initiating event (MIE; AR antagonism), the key events (LH increase, Leydig cell proliferation and hyperplasia increases) and associated events involved in the mode of action (MOA) of FLU induced testicular toxicity were characterized to address the dose response concordance. Results showed no effects at low doses (< 0.1 mg/kg/day) for the different key events studied. The histopathological changes (Leydig cell hyperplasia) observed at 1 and 10 mg/kg/day were associated with an increase in steroidogenesis gene expression in the testis from 1 mg/kg/day, as well as an increase in testosterone blood level at 10 mg/kg/day. Each key event dose–response was in good concordance with the MOA of FLU on the testis. From the available results, only monotonic dose–response curves were observed for the MIE, the key events, associated events and in effects observed in other sex related tissues. All the results, so far, show that the reference endocrine disruptor FLU induces threshold effects in a standard 28-day toxicity study on adult male rats. - Highlights: • Dose–response characterization of endocrine mediated toxicity is an on-going debate. • A wide range of dose levels of flutamide was evaluated on young adult male rats. • Flutamide induces threshold effects using on standard and molecular tools. The dose-response characterization of endocrine mediated toxicity is an on-going debate which is controversial when exploring the nature of the dose-response curve and the effect at the low-end of the curve. To contribute to this debate we have assessed the effects of a wide range of dose levels of the antiandrogen flutamide (FLU) on 7-week male Wistar rats. FLU was administered by oral gavage at doses of 0, 0.001, 0.01, 0.1, 1 and 10mg/kg/day for 28 days. To evaluate the reproducibility, the study was performed 3 times. The molecular initiating event (MIE; AR antagonism), the key events (LH increase, Leydig cell proliferation and hyperplasia increases) and associated events involved in the mode of action (MOA) of FLU induced testicular toxicity were characterized to address the dose response concordance. Results showed no effects at low doses (<0.1mg/kg/day) for the different key events studied. The histopathological changes (Leydig cell hyperplasia) observed at 1 and 10mg/kg/day were associated with an increase in steroidogenesis gene expression in the testis from 1mg/kg/day, as well as an increase in testosterone blood level at 10mg/kg/day. Each key event dose-response was in good concordance with the MOA of FLU on the testis. From the available results, only monotonic dose-response curves were observed for the MIE, the key events, associated events and in effects observed in other sex related tissues. All the results, so far, show that the reference endocrine disruptor FLU induces threshold effects in a standard 28-day toxicity study on adult male rats. The dose–response characterization of endocrine mediated toxicity is an on-going debate which is controversial when exploring the nature of the dose–response curve and the effect at the low-end of the curve. To contribute to this debate we have assessed the effects of a wide range of dose levels of the antiandrogen flutamide (FLU) on 7-week male Wistar rats. FLU was administered by oral gavage at doses of 0, 0.001, 0.01, 0.1, 1 and 10mg/kg/day for 28days. To evaluate the reproducibility, the study was performed 3 times. The molecular initiating event (MIE; AR antagonism), the key events (LH increase, Leydig cell proliferation and hyperplasia increases) and associated events involved in the mode of action (MOA) of FLU induced testicular toxicity were characterized to address the dose response concordance. Results showed no effects at low doses (<0.1mg/kg/day) for the different key events studied. The histopathological changes (Leydig cell hyperplasia) observed at 1 and 10mg/kg/day were associated with an increase in steroidogenesis gene expression in the testis from 1mg/kg/day, as well as an increase in testosterone blood level at 10mg/kg/day. Each key event dose–response was in good concordance with the MOA of FLU on the testis. From the available results, only monotonic dose–response curves were observed for the MIE, the key events, associated events and in effects observed in other sex related tissues. All the results, so far, show that the reference endocrine disruptor FLU induces threshold effects in a standard 28-day toxicity study on adult male rats. •Dose–response characterization of endocrine mediated toxicity is an on-going debate.•A wide range of dose levels of flutamide was evaluated on young adult male rats.•Flutamide induces threshold effects using on standard and molecular tools. |
Author | Hilmi, C. Tinwell, H. Schorsch, F. Rouquié, D. Bars, R. Pallardy, M. Sarrabay, A. |
Author_xml | – sequence: 1 givenname: A. surname: Sarrabay fullname: Sarrabay, A. organization: INSERM, Université Paris-Sud, Faculté de Pharmacie, Châtenay-Malabry, France – sequence: 2 givenname: C. surname: Hilmi fullname: Hilmi, C. organization: Bayer SAS, 16, rue Jean Marie Leclair, 69009 Lyon, France – sequence: 3 givenname: H. surname: Tinwell fullname: Tinwell, H. organization: Bayer SAS, 16, rue Jean Marie Leclair, 69009 Lyon, France – sequence: 4 givenname: F. surname: Schorsch fullname: Schorsch, F. organization: Bayer SAS, 16, rue Jean Marie Leclair, 69009 Lyon, France – sequence: 5 givenname: M. surname: Pallardy fullname: Pallardy, M. organization: INSERM, Université Paris-Sud, Faculté de Pharmacie, Châtenay-Malabry, France – sequence: 6 givenname: R. surname: Bars fullname: Bars, R. organization: Bayer SAS, 16, rue Jean Marie Leclair, 69009 Lyon, France – sequence: 7 givenname: D. surname: Rouquié fullname: Rouquié, D. email: david.rouquie@bayer.com organization: Bayer SAS, 16, rue Jean Marie Leclair, 69009 Lyon, France |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26485406$$D View this record in MEDLINE/PubMed https://www.osti.gov/biblio/22687856$$D View this record in Osti.gov |
BookMark | eNp9kMFq3DAURUVJaSZpf6CLIuimG0-fJEu2oZsQ0qYwpZsEshOy_JTR4JGmlpzQv4_cSbPM6sHl3MvjnJGTEAMS8pHBmgFTX3frbMxhzYHJEqwBujdkxaBTFQghTsgKoGYVQHt3Ss5S2kEh6pq9I6dc1a2sQa3I7SY-0iEmpPhgxtlkHwONjuYtUhOyN2GY4j0G6sY5m70fkLo4jvHRh3tq6K9YgoJf2H9FczhM0djte_LWmTHhh-d7Tm6_X91cXleb3z9-Xl5sKluzJldO9IMC46yyKGUnGoeuh6YT0rFGOd4L23SDkwa5azsDAlXLTV9LK7jAdhDn5PNxN6bsdbI-o93aGALarDlXbdNKVagvR6o892fGlPXeJ4vjaALGOWnWSMYZk7Cg_IjaKaY0odOHye_N9Fcz0It0vdOLdL1IX7KitJQ-Pe_P_R6Hl8p_ywX4dgSwuHjwOC2vYrA4-Gn5dIj-tf0ndnqUwg |
CitedBy_id | crossref_primary_10_1080_03639045_2023_2182124 crossref_primary_10_1186_s12958_020_00582_3 crossref_primary_10_3390_ijms21124439 crossref_primary_10_1093_toxsci_kfx135 crossref_primary_10_1016_j_bmcl_2020_127507 crossref_primary_10_56766_ntms_1441182 crossref_primary_10_1134_S1990519X21040088 crossref_primary_10_1016_j_comtox_2019_100098 crossref_primary_10_1016_j_surfin_2023_103195 crossref_primary_10_1038_s41598_021_93292_8 |
Cites_doi | 10.1016/j.chemosphere.2013.06.043 10.1016/j.taap.2014.01.017 10.1124/dmd.105.009159 10.1095/biolreprod.104.039321 10.1038/490462a 10.1002/1097-0142(19931215)72:12+<3816::AID-CNCR2820721711>3.0.CO;2-3 10.1007/s00204-010-0640-7 10.1093/toxsci/kfp056 10.1016/j.envpol.2013.07.046 10.1007/s002040050664 10.3109/10408444.2010.541225 10.1210/er.2008-0021 10.1016/B978-0-12-800095-3.00005-5 10.1210/er.2011-1050 10.1016/0002-9343(92)90741-S 10.1093/toxsci/kfm022 10.1289/ehp.0900887 10.1007/s002040100214 10.1124/dmd.105.008623 10.3109/10408444.2014.931925 10.1006/rtph.2001.1493 10.1093/toxsci/kfr099 |
ContentType | Journal Article |
Copyright | 2015 Elsevier Inc. Copyright © 2015 Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2015 Elsevier Inc. – notice: Copyright © 2015 Elsevier Inc. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7U7 C1K OTOTI |
DOI | 10.1016/j.taap.2015.10.009 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Toxicology Abstracts Environmental Sciences and Pollution Management OSTI.GOV |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Toxicology Abstracts Environmental Sciences and Pollution Management |
DatabaseTitleList | Toxicology Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1096-0333 |
EndPage | 524 |
ExternalDocumentID | 22687856 10_1016_j_taap_2015_10_009 26485406 S0041008X15301125 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .~1 0R~ 123 1B1 1RT 1~. 1~5 4.4 457 4G. 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKC AAIKJ AAKOC AALRI AAMNW AAOAW AAQFI AATCM AAXUO ABFRF ABFYP ABJNI ABLST ABMAC ABYKQ ABZDS ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AHEUO AIEXJ AIKHN AITUG AJBFU AJOXV AKIFW ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLECG BLXMC C45 CS3 DM4 EBS EFBJH EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IHE J1W KCYFY KOM LG5 M33 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 RIG ROL RPZ SDF SDG SDP SES SPCBC SSJ SSP SSZ T5K TEORI TWZ WH7 ZU3 ~G- AAXKI AKRWK CGR CUY CVF ECM EIF NPM .55 .GJ .HR 29Q 3O- 53G AAQXK AAYXX ABEFU ABFNM ABXDB ADFGL ADMUD AFFNX AFJKZ AHHHB ASPBG AVWKF AZFZN CAG CITATION COF FEDTE FGOYB G-2 HMT HVGLF HZ~ R2- SEW SPT UHS WUQ X7M XJT XPP Y6R YCJ ZGI ZKB ZMT ZXP ~KM 7U7 C1K AALMO AAPBV ABPIF ABPTK ABQIS EFJIC OTOTI |
ID | FETCH-LOGICAL-c417t-f3bd60afc6ce55937fefb07935f176f2b3c79df5ae2f89a03e682ab45c323e8d3 |
IEDL.DBID | .~1 |
ISSN | 0041-008X |
IngestDate | Thu May 18 22:32:34 EDT 2023 Fri Oct 25 07:39:09 EDT 2024 Thu Sep 26 19:22:21 EDT 2024 Sat Sep 28 07:57:33 EDT 2024 Fri Feb 23 02:29:39 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Low-dose Flutamide Leydig cell hyperplasia Mode of action Threshold |
Language | English |
License | Copyright © 2015 Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c417t-f3bd60afc6ce55937fefb07935f176f2b3c79df5ae2f89a03e682ab45c323e8d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 26485406 |
PQID | 1751211506 |
PQPubID | 23462 |
PageCount | 10 |
ParticipantIDs | osti_scitechconnect_22687856 proquest_miscellaneous_1751211506 crossref_primary_10_1016_j_taap_2015_10_009 pubmed_primary_26485406 elsevier_sciencedirect_doi_10_1016_j_taap_2015_10_009 |
PublicationCentury | 2000 |
PublicationDate | 2015-12-15 |
PublicationDateYYYYMMDD | 2015-12-15 |
PublicationDate_xml | – month: 12 year: 2015 text: 2015-12-15 day: 15 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Toxicology and applied pharmacology |
PublicationTitleAlternate | Toxicol Appl Pharmacol |
PublicationYear | 2015 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Myers, Zoeller, vom Saal (bb0110) 2009; 117 Carmichael, Bausen, Boobis, Cohen, Embry, Fruijtier-Pölloth, Greim, Lewis, Bette Meek, Mellor, Vickers, Doe (bb0035) 2011; 41 Labrie (bb0085) 1993; 72 Beausoleil, Ormsby, Gies, Hass, Heindel, Holmer, Nielsen, Munn, Schoenfelder (bb0025) 2013; 93 Sonich-Mullin, Fielder, Wiltse, Baetcke, Dempsey, Fenner-Crisp, Grant, Hartley, Knaap, Kroese, Mangelsdorf, Meek, Rice, Younes (bb0170) 2001; 34 Council (bb0050) 2014 Friry-Santini, Rouquié, Kennel, Tinwell, Benahmed, Bars (bb0065) 2007; 97 Vandenberg (bb0195) 2014 Schering (bb0145) 2000 Goda, Nagai, Akiyama, Nishikawa, Ikemoto, Aizawa, Nagata, Yamazoe (bb0070) 2006; 34 European Chemicals Agency (bb0055) 2014 Gomez, Dupont, Cusan, Tremblay, Suburu, Lemay, Labrie (bb0075) 1992; 92 Toyoda, Shibutani, Tamura, Koujitani, Uneyama, Hirose (bb0185) 2000; 74 Calabrese (bb0030) 2013; 182 Simon, S., Preston, Boobis, Cohen, Doerrer, Fenner-Crisp, McMullin, McQueen, Rowlands, Dose-response (bb0155) 2014; 8444 Odum (bb0125) 2013 National Toxicology Program, U.S. Environmental Protection Agency (bb0115) 2001 Rouquié, Friry-Santini, Schorsch, Tinwell, Bars (bb0135) 2009; 109 Shimamoto, Dewa, Kemmochi, Taniai, Hayashi, Imaoka, Shibutani, Mitsumori (bb0150) 2011; 85 Andrews, Freyberger, Hartmann, Eiben, Loof, Schmidt, Temerowski, Becka (bb0005) 2001; 75 Simoni, Weinbauer, Gromoll, Nieschlag (bb0160) 1999; 60 Leone, Nie, Brandon Parker, Sawant, Piechta, Kelley, Mark Kao, Jim Proctor, Verheyen, Johnson, Lord, McMillian (bb0095) 2014; 275 Hass, Christiansen, Axelstad, Sørensen, Boberg (bb0080) 2013 Sufrin, Coffey (bb0180) 1976; 13 Royal Society of Chemistry (bb0140) 2014 OECD (bb0130) 2013 Autrup, Barile, Blaauboer, Degen, Dekant, Dietrich, Domingo, Gori, Greim, Hengstler, Kacew, Marquardt, Pelkonen, Savolainen, Vermeulen (bb0010) 2015 Ludwig, Tinwell, Schorsch, Cavaillé, Pallardy, Rouquié, Bars (bb0100) 2011; 122 Vandenberg, Maffini, Sonnenschein, Rubin, Soto (bb0205) 2009; 30 Wetherill, Petre, Monk, Puga, Knudsen (bb0210) 2002; 1 Coe, Nelson, Ulrich, He, Dai, Cheng, Caguyong, Roberts, Slatter (bb0045) 2006; 34 U.S. Environmental Protection Agency (bb0190) 2013 Meachem, Stanton, Schlatt (bb0105) 2005; 72 Fagin (bb0060) 2012; 490 Vandenberg, Colborn, Hayes, Heindel, Jacobs, Lee, Shioda, Soto, vom Saal, Welshons, Zoeller, Myers (bb0200) 2012; 33 Toyoda (10.1016/j.taap.2015.10.009_bb0185) 2000; 74 National Toxicology Program, U.S. Environmental Protection Agency (10.1016/j.taap.2015.10.009_bb0115) 2001 Vandenberg (10.1016/j.taap.2015.10.009_bb0195) 2014 Vandenberg (10.1016/j.taap.2015.10.009_bb0200) 2012; 33 Carmichael (10.1016/j.taap.2015.10.009_bb0035) 2011; 41 Labrie (10.1016/j.taap.2015.10.009_bb0085) 1993; 72 Ludwig (10.1016/j.taap.2015.10.009_bb0100) 2011; 122 Schering (10.1016/j.taap.2015.10.009_bb0145) 2000 Vandenberg (10.1016/j.taap.2015.10.009_bb0205) 2009; 30 Gomez (10.1016/j.taap.2015.10.009_bb0075) 1992; 92 Sufrin (10.1016/j.taap.2015.10.009_bb0180) 1976; 13 Hass (10.1016/j.taap.2015.10.009_bb0080) 2013 Calabrese (10.1016/j.taap.2015.10.009_bb0030) 2013; 182 Rouquié (10.1016/j.taap.2015.10.009_bb0135) 2009; 109 Leone (10.1016/j.taap.2015.10.009_bb0095) 2014; 275 OECD (10.1016/j.taap.2015.10.009_bb0130) 2013 Council (10.1016/j.taap.2015.10.009_bb0050) 2014 U.S. Environmental Protection Agency (10.1016/j.taap.2015.10.009_bb0190) 2013 Simoni (10.1016/j.taap.2015.10.009_bb0160) 1999; 60 Goda (10.1016/j.taap.2015.10.009_bb0070) 2006; 34 Myers (10.1016/j.taap.2015.10.009_bb0110) 2009; 117 Odum (10.1016/j.taap.2015.10.009_bb0125) 2013 Sonich-Mullin (10.1016/j.taap.2015.10.009_bb0170) 2001; 34 Wetherill (10.1016/j.taap.2015.10.009_bb0210) 2002; 1 Fagin (10.1016/j.taap.2015.10.009_bb0060) 2012; 490 Simon (10.1016/j.taap.2015.10.009_bb0155) 2014; 8444 Beausoleil (10.1016/j.taap.2015.10.009_bb0025) 2013; 93 Coe (10.1016/j.taap.2015.10.009_bb0045) 2006; 34 Royal Society of Chemistry (10.1016/j.taap.2015.10.009_bb0140) 2014 Andrews (10.1016/j.taap.2015.10.009_bb0005) 2001; 75 Shimamoto (10.1016/j.taap.2015.10.009_bb0150) 2011; 85 Friry-Santini (10.1016/j.taap.2015.10.009_bb0065) 2007; 97 Meachem (10.1016/j.taap.2015.10.009_bb0105) 2005; 72 European Chemicals Agency (10.1016/j.taap.2015.10.009_bb0055) 2014 Autrup (10.1016/j.taap.2015.10.009_bb0010) 2015 |
References_xml | – volume: 275 start-page: 189 year: 2014 end-page: 197 ident: bb0095 article-title: Oxidative stress/reactive metabolite gene expression signature in rat liver detects idiosyncratic hepatotoxicants publication-title: Toxicol. Appl. Pharmacol. contributor: fullname: McMillian – start-page: 45 year: 2013 ident: bb0130 article-title: Guidance document on developing and assessing Adverse Outcome Pathways publication-title: Iomc/Oecd 184 contributor: fullname: OECD – volume: 97 start-page: 81 year: 2007 end-page: 93 ident: bb0065 article-title: Correlation between protein accumulation profiles and conventional toxicological findings using a model antiandrogenic compound, flutamide publication-title: Toxicol. Sci. contributor: fullname: Bars – volume: 13 start-page: 429 year: 1976 end-page: 434 ident: bb0180 article-title: Flutamide. Mechanism of action of a new nonsteroidal antiandrogen publication-title: Investig. Urol. contributor: fullname: Coffey – volume: 85 start-page: 1159 year: 2011 end-page: 1166 ident: bb0150 article-title: Relationship between CYP1A induction by indole-3-carbinol or flutamide and liver tumor-promoting potential in rats publication-title: Arch. Toxicol. contributor: fullname: Mitsumori – volume: 8444 start-page: 17 year: 2014 end-page: 43 ident: bb0155 article-title: The use of mode of action information in risk assessment: quantitative key events/dose–response framework for modeling the dose–response for key events publication-title: Crit. Rev. Toxicol. contributor: fullname: Dose-response – volume: 93 start-page: 847 year: 2013 end-page: 856 ident: bb0025 article-title: Low dose effects and non-monotonic dose responses for endocrine active chemicals: science to practice workshop: workshop summary publication-title: Chemosphere contributor: fullname: Schoenfelder – volume: 72 start-page: 3816 year: 1993 end-page: 3827 ident: bb0085 article-title: Mechanism of action and pure antiandrogenic properties of flutamide publication-title: Cancer contributor: fullname: Labrie – year: 2000 ident: bb0145 article-title: Eulexin (Flutamide) Capsules Prescribing Information contributor: fullname: Schering – volume: 74 start-page: 127 year: 2000 end-page: 132 ident: bb0185 article-title: Repeated dose (28 publication-title: Arch. Toxicol. contributor: fullname: Hirose – year: 2001 ident: bb0115 article-title: National Toxicology Program's Report of the National Toxicology Program's Report of the Endocrine Disruptors Low-Dose Peer Review contributor: fullname: National Toxicology Program, U.S. Environmental Protection Agency – volume: 34 start-page: 146 year: 2001 end-page: 152 ident: bb0170 article-title: IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis publication-title: Regul. Toxicol. Pharmacol. contributor: fullname: Younes – start-page: 1 year: 2015 end-page: 5 ident: bb0010 article-title: Principles of pharmacology and toxicology also govern effects of chemicals on the endocrine system publication-title: Toxicol. Sci. contributor: fullname: Vermeulen – volume: 490 start-page: 5 year: 2012 end-page: 8 ident: bb0060 article-title: The learning curve publication-title: Nature contributor: fullname: Fagin – volume: 182 start-page: 452 year: 2013 end-page: 460 ident: bb0030 article-title: Biphasic dose responses in biology, toxicology and medicine: accounting for their generalizability and quantitative features publication-title: Environ. Pollut. contributor: fullname: Calabrese – volume: 60 start-page: 102 year: 1999 end-page: 106 ident: bb0160 article-title: Role of FSH in male gonadal function publication-title: Ann. Endocrinol. contributor: fullname: Nieschlag – volume: 75 start-page: 65 year: 2001 end-page: 73 ident: bb0005 article-title: Feasibility and potential gains of enhancing the subacute rat study protocol (OECD test guideline no. 407) by additional parameters selected to determine endocrine modulation. A pre-validation study to determine endocrine-mediated effects of the antiandro publication-title: Arch. Toxicol. contributor: fullname: Becka – volume: 41 start-page: 175 year: 2011 end-page: 186 ident: bb0035 article-title: Using mode of action information to improve regulatory decision-making: an ECETOC/ILSI RF/HESI workshop overview publication-title: Crit. Rev. Toxicol. contributor: fullname: Doe – volume: 109 start-page: 59 year: 2009 end-page: 65 ident: bb0135 article-title: Standard and molecular NOAELs for rat testicular toxicity induced by flutamide publication-title: Toxicol. Sci. contributor: fullname: Bars – year: 2014 ident: bb0140 article-title: Royal Society of Chemistry Expert Panel on Endocrine Disrupter Low Dose Effects RSC London 4 th June 2014 contributor: fullname: Royal Society of Chemistry – volume: 34 start-page: 828 year: 2006 end-page: 835 ident: bb0070 article-title: Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-(trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients. Rika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikem publication-title: Drug Metab. Dispos. contributor: fullname: Yamazoe – volume: 117 start-page: 1652 year: 2009 end-page: 1655 ident: bb0110 article-title: A clash of old and new scientific concepts in toxicity, with important implications for public health publication-title: Environ. Health Perspect. contributor: fullname: vom Saal – volume: 30 start-page: 75 year: 2009 end-page: 95 ident: bb0205 article-title: Bisphenol-a and the great divide: a review of controversies in the field of endocrine disruption publication-title: Endocr. Rev. contributor: fullname: Soto – year: 2014 ident: bb0195 article-title: Low-dose effects of hormones and endocrine disruptors publication-title: Vitamins and Hormones contributor: fullname: Vandenberg – year: 2013 ident: bb0080 article-title: Input for the REACH-review in 2013 on Endocrine Disrupters contributor: fullname: Boberg – year: 2014 ident: bb0055 article-title: Mode of Action and Human Relevance Framework in the Context of Classification and Labelling (CLH) and Regulatory Assessment of Biocides and Pesticides contributor: fullname: European Chemicals Agency – volume: 92 start-page: 465 year: 1992 end-page: 470 ident: bb0075 article-title: Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients publication-title: Am. J. Med. contributor: fullname: Labrie – volume: 72 start-page: 1187 year: 2005 end-page: 1193 ident: bb0105 article-title: Follicle-stimulating hormone regulates both Sertoli cell and spermatogonial populations in the adult photoinhibited Djungarian hamster testis publication-title: Biol. Reprod. contributor: fullname: Schlatt – volume: 34 start-page: 1266 year: 2006 end-page: 1275 ident: bb0045 article-title: Profiling the hepatic effects of flutamide in rats: a microarray comparison with classical aryl hydrocarbon receptor ligands and atypical CYP1A inducers publication-title: Drug Metab. Dispos. contributor: fullname: Slatter – year: 2014 ident: bb0050 article-title: Review of the environmental protection agency's state-of-the-science evaluation of nonmonotonic dose–response relationships as they apply to endocrine disrupters on earth contributor: fullname: Council – year: 2013 ident: bb0125 article-title: Low Dose Endocrine Dirsrupter Effects: Review of Substances for Further Study. Regulatory Science Associates, UK contributor: fullname: Odum – volume: 1 start-page: 515 year: 2002 end-page: 524 ident: bb0210 article-title: The xenoestrogen bisphenol a induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells publication-title: Mol. Cancer Ther. contributor: fullname: Knudsen – year: 2013 ident: bb0190 article-title: State of the Science Evaluation: Nonmonotonic Dose Responses as They Apply to Estrogen, Androgen, and Thyroid Pathways and EPA Testing and Assessment Procedures contributor: fullname: U.S. Environmental Protection Agency – volume: 122 start-page: 52 year: 2011 end-page: 63 ident: bb0100 article-title: A molecular and phenotypic integrative approach to identify a no-effect dose level for antiandrogen-induced testicular toxicity publication-title: Toxicol. Sci. contributor: fullname: Bars – volume: 33 start-page: 378 year: 2012 end-page: 455 ident: bb0200 article-title: Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses publication-title: Endocr. Rev. contributor: fullname: Myers – volume: 1 start-page: 515 year: 2002 ident: 10.1016/j.taap.2015.10.009_bb0210 article-title: The xenoestrogen bisphenol a induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells publication-title: Mol. Cancer Ther. contributor: fullname: Wetherill – volume: 93 start-page: 847 year: 2013 ident: 10.1016/j.taap.2015.10.009_bb0025 article-title: Low dose effects and non-monotonic dose responses for endocrine active chemicals: science to practice workshop: workshop summary publication-title: Chemosphere doi: 10.1016/j.chemosphere.2013.06.043 contributor: fullname: Beausoleil – volume: 275 start-page: 189 year: 2014 ident: 10.1016/j.taap.2015.10.009_bb0095 article-title: Oxidative stress/reactive metabolite gene expression signature in rat liver detects idiosyncratic hepatotoxicants publication-title: Toxicol. Appl. Pharmacol. doi: 10.1016/j.taap.2014.01.017 contributor: fullname: Leone – volume: 34 start-page: 1266 year: 2006 ident: 10.1016/j.taap.2015.10.009_bb0045 article-title: Profiling the hepatic effects of flutamide in rats: a microarray comparison with classical aryl hydrocarbon receptor ligands and atypical CYP1A inducers publication-title: Drug Metab. Dispos. doi: 10.1124/dmd.105.009159 contributor: fullname: Coe – volume: 72 start-page: 1187 year: 2005 ident: 10.1016/j.taap.2015.10.009_bb0105 article-title: Follicle-stimulating hormone regulates both Sertoli cell and spermatogonial populations in the adult photoinhibited Djungarian hamster testis publication-title: Biol. Reprod. doi: 10.1095/biolreprod.104.039321 contributor: fullname: Meachem – volume: 490 start-page: 5 year: 2012 ident: 10.1016/j.taap.2015.10.009_bb0060 article-title: The learning curve publication-title: Nature doi: 10.1038/490462a contributor: fullname: Fagin – volume: 72 start-page: 3816 year: 1993 ident: 10.1016/j.taap.2015.10.009_bb0085 article-title: Mechanism of action and pure antiandrogenic properties of flutamide publication-title: Cancer doi: 10.1002/1097-0142(19931215)72:12+<3816::AID-CNCR2820721711>3.0.CO;2-3 contributor: fullname: Labrie – volume: 85 start-page: 1159 year: 2011 ident: 10.1016/j.taap.2015.10.009_bb0150 article-title: Relationship between CYP1A induction by indole-3-carbinol or flutamide and liver tumor-promoting potential in rats publication-title: Arch. Toxicol. doi: 10.1007/s00204-010-0640-7 contributor: fullname: Shimamoto – volume: 109 start-page: 59 year: 2009 ident: 10.1016/j.taap.2015.10.009_bb0135 article-title: Standard and molecular NOAELs for rat testicular toxicity induced by flutamide publication-title: Toxicol. Sci. doi: 10.1093/toxsci/kfp056 contributor: fullname: Rouquié – volume: 182 start-page: 452 year: 2013 ident: 10.1016/j.taap.2015.10.009_bb0030 article-title: Biphasic dose responses in biology, toxicology and medicine: accounting for their generalizability and quantitative features publication-title: Environ. Pollut. doi: 10.1016/j.envpol.2013.07.046 contributor: fullname: Calabrese – volume: 74 start-page: 127 year: 2000 ident: 10.1016/j.taap.2015.10.009_bb0185 article-title: Repeated dose (28days) oral toxicity study of flutamide in rats, based on the draft protocol for the “Enhanced OECD Test Guideline 407” for screening for endocrine-disrupting chemicals publication-title: Arch. Toxicol. doi: 10.1007/s002040050664 contributor: fullname: Toyoda – volume: 13 start-page: 429 year: 1976 ident: 10.1016/j.taap.2015.10.009_bb0180 article-title: Flutamide. Mechanism of action of a new nonsteroidal antiandrogen publication-title: Investig. Urol. contributor: fullname: Sufrin – volume: 41 start-page: 175 year: 2011 ident: 10.1016/j.taap.2015.10.009_bb0035 article-title: Using mode of action information to improve regulatory decision-making: an ECETOC/ILSI RF/HESI workshop overview publication-title: Crit. Rev. Toxicol. doi: 10.3109/10408444.2010.541225 contributor: fullname: Carmichael – start-page: 45 year: 2013 ident: 10.1016/j.taap.2015.10.009_bb0130 article-title: Guidance document on developing and assessing Adverse Outcome Pathways contributor: fullname: OECD – year: 2014 ident: 10.1016/j.taap.2015.10.009_bb0055 contributor: fullname: European Chemicals Agency – volume: 30 start-page: 75 year: 2009 ident: 10.1016/j.taap.2015.10.009_bb0205 article-title: Bisphenol-a and the great divide: a review of controversies in the field of endocrine disruption publication-title: Endocr. Rev. doi: 10.1210/er.2008-0021 contributor: fullname: Vandenberg – year: 2000 ident: 10.1016/j.taap.2015.10.009_bb0145 contributor: fullname: Schering – year: 2014 ident: 10.1016/j.taap.2015.10.009_bb0195 article-title: Low-dose effects of hormones and endocrine disruptors doi: 10.1016/B978-0-12-800095-3.00005-5 contributor: fullname: Vandenberg – volume: 33 start-page: 378 year: 2012 ident: 10.1016/j.taap.2015.10.009_bb0200 article-title: Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses publication-title: Endocr. Rev. doi: 10.1210/er.2011-1050 contributor: fullname: Vandenberg – year: 2001 ident: 10.1016/j.taap.2015.10.009_bb0115 contributor: fullname: National Toxicology Program, U.S. Environmental Protection Agency – year: 2013 ident: 10.1016/j.taap.2015.10.009_bb0125 contributor: fullname: Odum – volume: 92 start-page: 465 year: 1992 ident: 10.1016/j.taap.2015.10.009_bb0075 article-title: Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients publication-title: Am. J. Med. doi: 10.1016/0002-9343(92)90741-S contributor: fullname: Gomez – year: 2013 ident: 10.1016/j.taap.2015.10.009_bb0190 contributor: fullname: U.S. Environmental Protection Agency – year: 2014 ident: 10.1016/j.taap.2015.10.009_bb0050 contributor: fullname: Council – volume: 60 start-page: 102 year: 1999 ident: 10.1016/j.taap.2015.10.009_bb0160 article-title: Role of FSH in male gonadal function publication-title: Ann. Endocrinol. contributor: fullname: Simoni – volume: 97 start-page: 81 year: 2007 ident: 10.1016/j.taap.2015.10.009_bb0065 article-title: Correlation between protein accumulation profiles and conventional toxicological findings using a model antiandrogenic compound, flutamide publication-title: Toxicol. Sci. doi: 10.1093/toxsci/kfm022 contributor: fullname: Friry-Santini – volume: 117 start-page: 1652 year: 2009 ident: 10.1016/j.taap.2015.10.009_bb0110 article-title: A clash of old and new scientific concepts in toxicity, with important implications for public health publication-title: Environ. Health Perspect. doi: 10.1289/ehp.0900887 contributor: fullname: Myers – year: 2013 ident: 10.1016/j.taap.2015.10.009_bb0080 contributor: fullname: Hass – volume: 75 start-page: 65 year: 2001 ident: 10.1016/j.taap.2015.10.009_bb0005 article-title: Feasibility and potential gains of enhancing the subacute rat study protocol (OECD test guideline no. 407) by additional parameters selected to determine endocrine modulation. A pre-validation study to determine endocrine-mediated effects of the antiandro publication-title: Arch. Toxicol. doi: 10.1007/s002040100214 contributor: fullname: Andrews – volume: 34 start-page: 828 year: 2006 ident: 10.1016/j.taap.2015.10.009_bb0070 article-title: Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-(trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients. Rika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikem publication-title: Drug Metab. Dispos. doi: 10.1124/dmd.105.008623 contributor: fullname: Goda – volume: 8444 start-page: 17 year: 2014 ident: 10.1016/j.taap.2015.10.009_bb0155 article-title: The use of mode of action information in risk assessment: quantitative key events/dose–response framework for modeling the dose–response for key events publication-title: Crit. Rev. Toxicol. doi: 10.3109/10408444.2014.931925 contributor: fullname: Simon – year: 2014 ident: 10.1016/j.taap.2015.10.009_bb0140 contributor: fullname: Royal Society of Chemistry – volume: 34 start-page: 146 year: 2001 ident: 10.1016/j.taap.2015.10.009_bb0170 article-title: IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis publication-title: Regul. Toxicol. Pharmacol. doi: 10.1006/rtph.2001.1493 contributor: fullname: Sonich-Mullin – volume: 122 start-page: 52 year: 2011 ident: 10.1016/j.taap.2015.10.009_bb0100 article-title: A molecular and phenotypic integrative approach to identify a no-effect dose level for antiandrogen-induced testicular toxicity publication-title: Toxicol. Sci. doi: 10.1093/toxsci/kfr099 contributor: fullname: Ludwig – start-page: 1 year: 2015 ident: 10.1016/j.taap.2015.10.009_bb0010 article-title: Principles of pharmacology and toxicology also govern effects of chemicals on the endocrine system publication-title: Toxicol. Sci. contributor: fullname: Autrup |
SSID | ssj0009441 |
Score | 2.2642114 |
Snippet | The dose–response characterization of endocrine mediated toxicity is an on-going debate which is controversial when exploring the nature of the dose–response... The dose-response characterization of endocrine mediated toxicity is an on-going debate which is controversial when exploring the nature of the dose-response... |
SourceID | osti proquest crossref pubmed elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 515 |
SubjectTerms | 60 APPLIED LIFE SCIENCES Androgen Antagonists - pharmacology ANIMAL TISSUES Animals ANTIANDROGENS BLOOD CELL PROLIFERATION Dose-Response Relationship, Drug DOSES EVALUATION Flutamide Flutamide - pharmacology Gene Expression - drug effects Leydig cell hyperplasia Leydig Cells - drug effects Low-dose Male Mode of action RATS Rats, Wistar Reproducibility of Results TESTES Testicular Diseases - blood Testicular Diseases - genetics TESTOSTERONE Testosterone - blood Threshold TOXICITY |
Title | Low dose evaluation of the antiandrogen flutamide following a Mode of Action approach |
URI | https://dx.doi.org/10.1016/j.taap.2015.10.009 https://www.ncbi.nlm.nih.gov/pubmed/26485406 https://search.proquest.com/docview/1751211506 https://www.osti.gov/biblio/22687856 |
Volume | 289 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT-MwEB2hckFarRbYjy4sMtKKyzaQxB9JjhUCFditemil3iInGUtF2gbRIsRlfzszcbIVBzhwjGVLlud5Zuy8eQb4GRVxKVEWAcVexaLaNkixSoIYUysxzOKiuRr4Mzajmbqe6_kWnHe1MEyrbH2_9-mNt25bztrVPLtbLLjGV7EyzZz2LIE05kJzReGPMH36b0PzyJTyr-YpOjZT77ZwxnO81tayZmWkTxuGV_ZacOrVtN9ez0GbWHT5CT62SaQY-nnuwhYu9-Bk4lWonwZiuimqWg3EiZhs9Kmf9uCDv6oTvgJpH2a_60dR1SsUG-lvUTtBqaGgdSf8VPc14Uw4Qqn9u6hQOEJP_UhRT1jBr6lx92FTISE6kfLPMLu8mJ6Pgva1haBUUbIOnCwqE1pXmhLpmCETh65g-TztosS4uJBlklVOW4xdmtlQokljWyhdylhiWskv0FvWS_wGAsPSRDaxtMFRKdY0k44ipeHznZOJ7sOvbpnzOy-qkXdss9ucjZKzUbiNjNIH3VkifwGNnLz-m-MO2Ww8hvVwSyYO0SDKN9Mk1aYPx505c9pS_J_ELrF-WOWUUbHwnQ6pz1dv5__TZEIgJbnm-zsndQA7_MWEmEgfQm99_4A_KK1ZF0cNbo9ge3h1Mxo_A-yQ9SE |
link.rule.ids | 230,315,783,787,888,4509,24128,27936,27937,45597,45691 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB6V9AASQlCgBFpYJNQLNbW9D9vHqKJKaRr1kEi5rdb2rBSkxlWTquq_Z8ZrE3Eoh17XO9Jq5_XteuZbgG9JmVYSZRlR7lVMqu2iHOssSjF3EuMiLdurgcupGc_Vr4Ve7MBp3wvDZZVd7A8xvY3W3chJt5snN8sl9_gqZqZZkM-Skab6GewSGijIO3dH5xfj6ZZ7V6nwcJ6ikzMJdL0zocxr4xzTVib6R1vkVTyWnwYNudzjMLRNR2ev4VWHI8UoLPUN7OBqD46uAhH1w7GYbfuq1sfiSFxtKaof9uBluK0ToQnpLcwnzb2omzWKLfu3aLwgdCho68mE6tuGTE14MlR3vaxReDKg5p4Sn3CCH1Tj6aO2SUL0POXvYH72c3Y6jroHF6JKJdkm8rKsTex8ZSqkk4bMPPqSGfS0TzLj01JWWVF77TD1eeFiiSZPXal0JVOJeS3fw2DVrPADCIwrk7jMkY-jUkxrJj0lS8NHPC8zPYTv_Tbbm8CrYfuCs9-WlWJZKTxGShmC7jVh_7EOS4H_v3IHrDaWYUrcimuHSIggZ57l2gzha69OS17Fv0rcCpu7tSVQxdx3OqY5-0HPf5fJNYGEc83HJy7qCzwfzy4ndnI-vfgEL_gL18ck-gAGm9s7PCSUsyk_d1b8B19S99U |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Low+dose+evaluation+of+the+antiandrogen+flutamide+following+a+Mode+of+Action+approach&rft.jtitle=Toxicology+and+applied+pharmacology&rft.au=Sarrabay%2C+A.&rft.au=Hilmi%2C+C.&rft.au=Tinwell%2C+H.&rft.au=Schorsch%2C+F.&rft.date=2015-12-15&rft.pub=Elsevier+Inc&rft.issn=0041-008X&rft.eissn=1096-0333&rft.volume=289&rft.issue=3&rft.spage=515&rft.epage=524&rft_id=info:doi/10.1016%2Fj.taap.2015.10.009&rft.externalDocID=S0041008X15301125 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0041-008X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0041-008X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0041-008X&client=summon |